204897 | Complement C4b, Human

204897
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      204897-250UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 250 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewNative, human C4b complement component. Cleavage of the C4 α-chain at peptide bond 77 by activated C1 enzyme results in the production of C4a (M.W. 8,758) and C4b (M.W. 193,000) fragments. The C4b fragment is a glycoprotein composed of the modified C4 α-chain (α′) and intact β- and γ-chains. Like C3b, C4b has the transient ability to form a covalent ester bond with a variety of target cell surfaces. Once bound to the target surface, C4b becomes an essential non-enzymatic subunit of the classical pathway C3 cleaving enzyme (C4b,C2a). In addition, surface bound C4b has opsonic and immune adherence activities which are mediated via binding to the CR1 (CD35) complement receptor which is found on a variety of inflammatory cells.
          Catalogue Number204897
          Brand Family Calbiochem®
          References
          ReferencesWeisman, H.F., et al. 1990. Science 249, 146.
          Holers, M.V., et al. 1985. Immunology Today 6, 188.
          Product Information
          FormLiquid
          FormulationIn PBS, pH 7.2.
          PreservativeNone
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          ContaminantsIgG, IgA, IgM, Factor B, Factor H, C3, ceruloplasmin, or albumin: ≤trace amounts
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          204897

          References

          Reference overview
          Weisman, H.F., et al. 1990. Science 249, 146.
          Holers, M.V., et al. 1985. Immunology Today 6, 188.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-May-2008 RFH
          DescriptionNative, human C4b complement component. Cleavage of the C4 α-chain at peptide bond 77 by activated C1 enzyme results in the production of C4a (M.W. 8,758) and C4b (M.W. 193,000) fragments. The C4b fragment is a glycoprotein composed of the modified C4 α-chain (α') and intact β- and γ-chains. Like C3b, C4b has the transient ability to form a covalent ester bond with a variety of target cell surfaces. Once bound to the target surface, C4b becomes an essential non-enzymatic subunit of the classical pathway C3 cleaving enzyme (C4b,C2a). In addition, surface bound C4b has opsonic and immune adherence activities, which are mediated via binding to the CR1 (CD35) complement receptor, which is found on a variety of inflammatory cells.
          FormLiquid
          FormulationIn PBS, pH 7.2.
          Concentration Label Please refer to vial label for lot-specific concentration
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Purity≥95% by SDS-PAGE
          ContaminantsIgG, IgA, IgM, Factor B, Factor H, C3, ceruloplasmin, or albumin: ≤trace amounts
          PreservativeNone
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesWeisman, H.F., et al. 1990. Science 249, 146.
          Holers, M.V., et al. 1985. Immunology Today 6, 188.